Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Brain Cancer treatment details. Biologic therapy. Chemotherapy. Duke University Medical Center, Durham, NC, United States

Survival: 4.4 months
Toxicity Grade: 4
Treatments: Biologic therapy
Country: United States
City/State/Province: Durham, NC
Hospital: Duke University Medical Center
Journal: Link
Date: 9/2010

This study involved a total of 23 glioblastoma multiforme patients who had progressed following previous treatment with bevacizumab. Patients were separated into 2 separate treatment groups. Group A consisted of 10 patients with a median age of 50.8 years and 70% male. Group B was made up of 13 patients with a median age of 52.4 years and 85% male.

Patients in group A were treated with the chemotherapeutic agent temozolomide and the biologic therapy agent bevacizumab, which is a monoclonal antibody that blocks cancer cell growth by targeting the vascular endothelial growth factor (VEGF) protein.

Patients in group B were treated with the chemotherapeutic agent etoposide and the biologic therapy agent bevacizumab.

The highest toxicity in group A was of grade 3, which was 1 case of grade 3 infection. In group B, there was 1 grade 4 toxicity reported, which was a case of neutropenia. Patients in this group also reported grade 2 and 3 fatigue (4 patients).

Median overall survival in group A was 12.6 months. For group B, the median overall survival was 19.0 months.

This study was partially supported by Genentech Pharmaceuticals, makers of Avastin (trade name for bevacizumab).

Correspondence: Dr. David A. Reardon; email:

E-mail to a Friend Email Physician More Information